Telephone
1.833.462.8482
Address
Suite 220 28159 Avenue Stanford Valencia, CA 91355
Description
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.88 - 6.27
Trade Value (12mth)
AU$326,994.00
1 week
1.23%
1 month
12.24%
YTD
70.98%
1 year
75.07%
All time high
104.137
EPS 3 yr Growth
1006.800%
EBITDA Margin
-84.90%
Operating Cashflow
-$26m
Free Cash Flow Return
-18.90%
ROIC
-27.40%
Interest Coverage
-1,825.80
Quick Ratio
8.00
Shares on Issue (Fully Dilluted)
127m
HALO Sector
Healthcare
Next Company Report Date
22-Feb-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.85
Date | Announcements |
---|---|
31 October 18 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 October 18 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
31 October 17 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 22 |
Form 8-K Material terms of CEO's Employment Agreement
×
Form 8-K Material terms of CEO's Employment Agreement |
30 October 20 |
Adjournment of 2020 Annual Stockholder Meeting
×
Adjournment of 2020 Annual Stockholder Meeting |
30 October 17 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 October 14 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 November 18 |
Avita Medical Annual General Meeting Presentation
×
Avita Medical Annual General Meeting Presentation |
30 November 18 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 November 17 |
Avita Medical Annual General Meeting Presentation
×
Avita Medical Annual General Meeting Presentation |
30 November 17 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 November 16 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 November 15 |
2015 CEO AGM Presentation Adam Kelliher
×
2015 CEO AGM Presentation Adam Kelliher |
30 November 10 |
AGM CEO Presentation
×
AGM CEO Presentation |
30 March 21 |
15 RECELL Abstracts Accepted at 53rd Annual ABA Meeting
×
15 RECELL Abstracts Accepted at 53rd Annual ABA Meeting |
30 June 23 |
AVITA Medical Submits FDA PMA Supplement for RECELL GO
×
AVITA Medical Submits FDA PMA Supplement for RECELL GO |
30 June 23 |
Notification regarding unquoted securities - AVH
×
Notification regarding unquoted securities - AVH |
30 June 23 |
Notice under section 708A(5)(e) of the Corporations Act
×
Notice under section 708A(5)(e) of the Corporations Act |
30 July 20 |
AVITA to Present at Canaacord Genuity Growth Conference
×
AVITA to Present at Canaacord Genuity Growth Conference |
30 January 18 |
Avita has Five Abstracts Accepted for ABA Annual Meeting
×
Avita has Five Abstracts Accepted for ABA Annual Meeting |
30 December 21 |
Change of Director's Interest Notice-James Corbett
×
Change of Director's Interest Notice-James Corbett |
30 December 21 |
Change of Director's Interest Notice-Jan Stern Reed
×
Change of Director's Interest Notice-Jan Stern Reed |
30 December 21 |
Change of Director's Interest Notice-Jeremy Curnock Cook
×
Change of Director's Interest Notice-Jeremy Curnock Cook |
30 December 21 |
Change of Director's Interest Notice-Louis Drapeau
×
Change of Director's Interest Notice-Louis Drapeau |
30 December 21 |
Change of Director's Interest Notice-Louis Panaccio
×
Change of Director's Interest Notice-Louis Panaccio |
30 December 21 |
Change of Director's Interest Notice-Michael Perry
×
Change of Director's Interest Notice-Michael Perry |
30 December 21 |
Change of Director's Interest Notice-Suzanne Crowe
×
Change of Director's Interest Notice-Suzanne Crowe |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.